SG&A Efficiency Analysis: Comparing ImmunityBio, Inc. and Evotec SE

Biotech Giants' SG&A Efficiency: A Decade of Insights

__timestampEvotec SEImmunityBio, Inc.
Wednesday, January 1, 2014179900004326000
Thursday, January 1, 201525166000226206000
Friday, January 1, 20162701300094391000
Sunday, January 1, 20174238300053821000
Monday, January 1, 20185701200035463000
Tuesday, January 1, 20196654600046456000
Wednesday, January 1, 20207723800071318000
Friday, January 1, 2021105445000135256000
Saturday, January 1, 2022156190000102708000
Sunday, January 1, 2023169610000129620000
Loading chart...

In pursuit of knowledge

SG&A Efficiency: A Tale of Two Biotech Giants

In the ever-evolving biotech landscape, understanding operational efficiency is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of ImmunityBio, Inc. and Evotec SE from 2014 to 2023. Over this period, Evotec SE's SG&A expenses surged by approximately 843%, reflecting its strategic expansion and operational scaling. In contrast, ImmunityBio, Inc. experienced a more volatile trajectory, with a peak in 2015, where expenses skyrocketed by over 5000% compared to 2014, before stabilizing in recent years. By 2023, Evotec SE's expenses were about 31% higher than ImmunityBio's, indicating a more consistent growth pattern. This comparison highlights the diverse strategies these companies employ in managing operational costs, offering insights into their financial health and strategic priorities.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025